Pharmacy Clinical Pearl of the Day: Direct Oral Anticoagulants and Bleeding Risk


When direct oral anticoagulants are taken, especially for the first time, patients may be at risk of bleeding.

Clinical Pearl of the Day: Direct oral anticoagulants (DOACs) and bleeding risk


  • dabigatran (Pradaxa)
  • rivaroxaban (Xarelto)
  • apixaban (Eliquis)
  • edoxaban (Savaysa)
  • betrixaban (Bevyxxa)

These agents are associated with a higher risk of gastrointestinal bleeding.


  • When DOACs are taken, especially for the first time, patients may be at risk of bleeding.
  • Bleeding symptoms may include:
    • Black or tarry stool
    • Bright red blood in vomit
    • Cramps in abdomen
    • Dizziness or faintness
    • Paleness
    • Shortness of breath

It is especially important that patients are educated on the bleeding risk when taking DOACs and, if they notice any, to refer back to their pharmacist or physician as soon as possible.


Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges | Journal of the American Heart Association (

Related Videos
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U -
Image credit: Andrea Izzotti
Inflation Reduction Act is shown using the text and the US flag - Image credit: Andrii |
Pharmacy Interior | Image Credit: Tyler Olson -
Patient preparing to undergo dialysis
Male pharmacist selling medications at drugstore to a senior woman customer | Image Credit: Zamrznuti tonovi -
Pharmacist assists senior woman in buying medicine in pharmacy - Image credit: Drazen |
Pharmacy, medicine and senior woman consulting pharmacist on prescription. Healthcare, shopping and elderly female in consultation with medical worker for medication box, pills or product in store - Image credit: C Daniels/ |
Image credit: fidaolga -
Pharmacists checking inventory at hospital pharmacy- Image credit: Jacob Lund |
Related Content
© 2023 MJH Life Sciences

All rights reserved.